Regardless of the reasons for these infections, we concur with the conclusion of Theis and Rhodes [30] that, despite screening and efforts to treat latent infections, clinicians need to carefully monitor for the emergence of tuberculosis infections in patients receiving anti-TNF-α therapies. Here, TNF is linked to disease arising from reactivation of latent virus.